SOHO 2023 | IMPROVE study: MRD assessment as an endpoint to define treatment length and intensity in CLL
Paolo Ghia
• 7 Sep 2023
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, discusses findings from the Phase II IMPROVE study (NCT04754035) and highlights the efficacy of utilizing measurable residual disease (MRD) as an endpoint to define the length and intensity of treatment for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
